TrialThe Lancet. Oncology2020

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Franck Morschhauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.